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Significance of serum palmitoleic 
acid levels in inflammatory bowel 
disease
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Naoyuki Yamaguchi4, Hisayoshi Kondo5, Fumihiko Fujita6, Hiroaki Takeshita7, 
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Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn’s disease (CD), are 
chronic intestinal diseases of unknown etiology that present with variable disease extents and 
outcomes. The use of biomarkers for the diagnosis and management of IBDs is considered beneficial. 
Palmitoleic acid (PO) is an adipose tissue-derived mono-unsaturated free fatty acid that potentially 
serves as a lipokine in metabolic and inflammatory diseases. The aim of this study was to investigate 
the significance of PO levels in the serum of patients with UC and CD. The study included patients 
with UC (n = 22), patients with CD (n = 35), and controls (n = 22). The levels of serum PO were analyzed 
using gas chromatography. The association of serum PO levels with the clinical features and disease 
outcomes in IBD was examined. Serum PO levels were significantly higher in patients with CD than in 
controls, whereas no difference in these levels was observed between patients with UC and controls. 
Serum PO levels were significantly associated with the CD activity index. Additionally, high serum PO 
levels were associated with an increased risk of surgical intervention requirement during follow-up. In 
a pilot study with a few patients, high PO levels were observed in the mesenteric tissue in the active 
disease site of patients with CD (n = 7) compared with those with colon cancer (n = 6). Elevated serum 
PO levels might serve as a marker for local inflammation and prognosis in patients with CD.
Ulcerative colitis (UC) and Crohn’s disease (CD) are inflammatory bowel diseases (IBDs). They exhibit similar 
clinical manifestations; however, only the mucosal layer in the large intestine is affected in  UC1, whereas the entire 
gastrointestinal system may be involved in  CD1. Both diseases often require long-term treatments, including 
5-aminosalicylic acid (5-ASA), immune-suppressor, and anti-tumor necrosis factor-alpha (TNF-α) administra-
tion. Failure to control flare ups and induce remission with drug therapy can necessitate surgical interventions, 
including colectomy, enterectomy, and abscess  drainage2. The severity and persistence of IBD markedly vary 
among the patients; it is difficult to assess the prognosis of the disease, especially, the risk for surgical intervention. 
Therefore, identifying a potential biomarker for assessing the prognosis of IBDs is of clinical interest.
The etiology of UC and CD is still unknown; however, microbial agents, immune dysfunction, genetic suscep-
tibility, and environmental factors, such as diet, are implicated as pathogenic  factors3. Luminal antigens induce 
abnormal immune responses, including intestinal inflammation, reactive oxygen species production, and circu-
lation of inflammatory mediators, such as  cytokines3. Inflammation localized in the intestine wall may radiate 
to the surrounding visceral adipose tissue, resulting in the proliferation and activation of adipocytes, especially 
in  CD4. The activation of adipocytes releases subsets of fat-derived hormones, such as vaspin and adiponectin. 
These hormones influence gastrointestinal immune responses by modulating the expression of proinflamma-
tory interleukins and adhesion factors, especially, TNF-α, which plays a crucial role in the pathogenesis of  IBD5.
Lipids are increasingly recognized as key components of multiple signal transduction cascades, including 
those associated with the regulation of inflammation. The levels of free fatty acids, especially poly-unsaturated 
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fatty acids (PUFAs), are dysregulated in the serum of patients with IBD. The levels of n-3 and n-6 PUFAs, precur-
sors of eicosanoids that are critical in modulating inflammation, are positively correlated with disease severity 
and pro-inflammatory cytokine  levels6–9.
Palmitoleic acid (PO) is a non-essential omega-7 monounsaturated free fatty acid. It is the third most common 
unsaturated free fatty acid in the human serum, after oleic acid (OA) and palmitic acid (PA). PO is an adipose 
tissue-derived lipid hormone (lipokine) that improves insulin  sensitivity10–14. The role of PO in immunity remains 
largely unexplored; however, several studies have shown that PO mainly influences anti-inflammatory responses. 
Incubation with PO has been reported to reverse the expression of proinflammatory factors and secretion of 
cytokines during proinflammatory polarization in bone marrow-derived macrophages obtained from high-fat 
diet-fed  mice15. PO reduces nuclear factor-kappa B phosphorylation and downregulates interleukin (IL)-6 and 
tumor necrosis factor (TNF)-α expression in hepatocytes and inflammatory  cells16. Nevertheless, Wang et al. 
used cross-phenotype analysis of genome-wide association studies to show that high serum PA levels could be 
associated with an increased risk of developing CD. They also showed that PO tended to increase neutrophil 
recruitment in 2,4,6-trinitrobenezene sulfonic acid-induced colitis in  zebrafish17. High serum PO levels have been 
observed in diseases involving metabolic dysregulation and inflammation, such as non-alcoholic steatohepatitis, 
hypertension, and heart  failure12,18. Thus, PO could be a potential clinical marker for inflammatory diseases.
There is a growing interest in the role of fatty acids in metabolic and inflammatory diseases; however, the 
association between serum PO levels and IBD severity and prognosis remains unexplored. In this study, we 
aimed to elucidate the role of PO levels in the serum of patients with IBD and its potential for use as a clinical 
biomarker for IBD.
Results
Patient characteristics. The patient characteristics are summarized in Table 1. Among the study partici-
pants, 22 patients (12 men and 10 women) had UC, 35 (24 men and 11 women) had CD, 7 (3 men and 4 women) 
had colon cancer, and 22 (17 men and 5 women) were healthy controls. Patients in the UC group (median, 
45 years; range 19–66 years) were significantly older than those in the CD (median, 32 years; range 17–55 years) 
and control (median, 27 years; range 22–54 years) groups. Patients in the colon cancer group (median, 67 years; 
range 52–87 years) were older than those in the UC and CD groups. The body mass index (BMI) of the patients 
in the CD group (median, 19.1; range 16.0–27.1) was significantly lower than that of the controls (median, 21.9; 
range 18.0–26.9).
Disease status and treatment at the time of sample collection are shown in Table 2. Twelve patients with CD 
had a Crohn’s disease activity index (CDAI) score of ≥ 150, and 11 patients with UC had a clinical activity index 
(CAI) score of ≥ 6. Infliximab and 5-ASA were the most common treatments used by patients with CD, and 
steroid immunosuppressants and 5-ASA were the most common treatments used by patients with UC.
Table 1.  Clinical characteristics of the patients in this study. CD Crohn’s disease, UC ulcerative colitis, CC 
colon cancer, NC normal control, BMI body mass index, CDAI Crohn’s disease activity index, CAI clinical 
activity index, 5-ASA 5-aminosalicylic acid, GCAP granulocytapheresis, LCAP leukocytapheresis.
CD UC CC NC
No. 37 25 7 22
Sex
Male 26 14 3 17
Female 11 11 4 5
Age (range; in years) 32 (17–55) 45 (19–66) 67 (52–87) 27 (22–54)
BMI (range; in kg/m2) 19.1(16.0–27.1) 21.9 (13.7–36.9) 20.6 (19.6–23.2) 21.9 (18.0–26.9)
CDAI
 ≥ 150 12 – – –
 < 150 25 – – –
CAI
 ≥ 6 – 11 – –
 < 6 – 14 – –
Current treatment
5-ASA 12 17 – –
Steroid 5 12 – –
Azathioprine 6 7 – –
Infliximab 13 0 – –
GCAP/LCAP 1 2 – –
Tacrolimus 0 2 – –
Elemental diet 15 0 – –
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Serum PO levels in patients with IBD. Serum PO levels in the UC, CD, and control groups are shown 
in Fig. 1. Serum PO levels were significantly higher in patients in the CD group than those in the control group, 
whereas these levels were not significantly different between the UC and healthy control groups. In contrast, 
serum levels of OA and PA, the two major free fatty acids, did not differ among the control, UC, and CD groups.
Based on these results, we assessed the factors that might affect PO level in patients with CD. Age, BMI, and 
C-reactive protein (CRP) levels did not have a significant correlation with PO levels, whereas the CDAI, which 
reflects disease severity, showed a moderate positive correlation with PO levels (Fig. 2). Ongoing treatment at 
the time of serum collection, such as the use of an elemental diet or anti-TNF-α agents and history of disease-
associated surgery, did not significantly affect the levels of PO in the serum (Fig. 3).
Association between PO and CD prognosis. Next, we assessed whether PO levels are related to IBD 
prognosis. This assessment involved patients who underwent surgical intervention after sample collection for 
multivariate Cox regression modeling (Table 2). Of the 35 patients with CD, 11 underwent surgical interven-
tions, such as ileectomy, colectomy, abscess drainage, and fistula resection, during the follow-up. The follow-up 
period was 8–4080 days. PO was an independent risk factor for surgical intervention. Other factors, such as age, 
sex, anti-TNF-α agent use, CRP levels, and history of prior surgery, were not significantly associated with surgi-
cal intervention after serum collection (Table 2). The area under the receiver operating curve (AUC) for serum 
PO levels for individuals requiring surgical intervention was 0.73. When the appropriate baseline PO threshold 
was set at 68 µg/ml, based on the YOUDEN index, the sensitivity for predicting the need for surgical interven-
tion was 72.1%, and the specificity was 75%.
PO levels in the mesenteric adipose tissue. To investigate the potential source of serum PO, the levels 
of PO in the mesenteric adipose tissue (MAT) was studied in patients with IBD in a pilot study; patients with 
colon cancer (non-tumor area) were included in the control group. PO levels in the site of active disease in 
patients with CD were significantly higher than those in the MAT of patients with colon cancer (p < 0.0224, 
Fig. 4A). PO levels did not significantly differ in the MAT between patients with UC and those with colon cancer, 
showing a pattern similar to that in the serum. Within the CD group, PO levels were significantly higher in the 
active disease site than in the unaffected area (Fig. 4B).
Table 2.  Cox-hazard model showing the hazard risk of surgical procedures in patients with CD. CI confidence 
interval, PO palmitoleate acid, BMI body mass index, CRP C-reactive protein.
HR P 95% CI
PO µg/ml (by 10 µg/ml) 1.2782499 0.0244 1.0544814–1.663221
Previous surgery 0.9727294 0.9801 0.1109397–8.5289769
Use of anti-TNF-α agents 0.8883578 0.8852 0.1780416–4.4325586
Disease duration (months) 0.996789 0.6553 0.981503–1.010695
Age 0.977114 0.6976 0.860438–1.095513
BMI 0.834017 0.2558 0.567761–1.096203
Female sex 2.6849704 0.3168 0.3882601–18.567622
CRP 1.273887 0.0994 0.95395–1.7419
Figure 1.  Elevation of serum palmitoleic acid (PO) levels in the serum of patients with Crohn’s disease (CD). 
Serum PO, oleic acid (OA), and palmitic acid (PA) levels were compared between patients with CD and healthy 
controls (control). The p-values in the graph show significant differences determined using the Steel–Dwass test.
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Figure 2.  Serum palmitoleic acid levels correlate with Crohn’s disease activity index (CDAI) scores in patients 
with Crohn’s disease (CD). Correlation between palmitoleic acid (PO) levels and age, body mass index (BMI), 
C-reactive protein (CRP), or the Crohn Disease Activity index (CDAI) score in patients with CD. The p-values 
in the graph show significant differences determined using the Spearman’s test.
Figure 3.  Serum palmitoleic acid (PO) levels are not affected by the history of elemental diet, surgery, or TNF-α 
treatment in patients with Crohn’s disease (CD). Comparison of serum PO levels among patients with CD based 
on the following factors: elemental diet, surgery history, and anti-TNF-α treatment. No significant difference 
between groups was observed based on the Wilcoxon test.
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Discussion
In this study, we found serum PO levels to be significantly higher in patients with CD than in healthy controls; 
serum PO levels were positively correlated with disease activity in patients with CD but were not correlated with 
BMI or elemental diet, which are the possible factors besides disease activity that can affect PO levels. Elevated 
serum PO levels were associated with an increased risk of requiring surgical intervention.
PO has garnered attention in recent years because of its potential role as an  adipokine13,15,19. Studies have 
indicated that circulating PO levels are associated with multiple metabolic risk factors and inflammatory diseases 
but in mixed directions, perhaps related to diversified lifestyle determinants or an endogenous source of fatty 
acids in  humans14,18,20.
The lipid profile is altered in both the serum and adipose tissue in patients with  IBDs3,4,21. A high ratio of PO 
to linoleic acid levels has been reported in children with  CD3; its relevance to the clinical severity and course of 
CD in adults is poorly understood. To the best of our knowledge, the present study is among the first to analyze 
the detailed relationship between PO levels and IBD, with reference to disease activity and prognosis.
We observed elevated serum PO levels only in patients with CD, in comparison with its levels in the control 
subjects. The other two major free fatty acids, PA and OA, remained stable in the serum of patients with CD; 
therefore, PO could be a potential biomarker reflecting the disease status in CD. In addition, PO levels did not 
exhibit an association with BMI or elemental diet; therefore, PO levels do not merely reflect the nutritional status 
of the patients. Interestingly, circulating PO levels were associated with the CDAI as well as levels of CRP, which 
is a general inflammation marker. These results suggest that PO serves as an optimal biomarker for determining 
the clinical severity of CD. The CDAI score includes the severity of abdominal pain and incidence of diarrhea, 
the occurrence of which in patients must be recorded for 1 week. In addition, data comprising BMI and blood 
hematocrit levels are necessary, and physicians are required to confirm the absence or presence of abdominal 
mass. Therefore, serum PO level may be beneficial to estimate the inflammation state in patients with CD when 
the collection of necessary information is challenging. In addition, our study showed that PO levels serve as a 
significant indicator for the need of later surgical procedures, which might be helpful in identifying high-risk 
cases that are prone to drug therapy failure. Thus, PO levels could alert physicians regarding the risk of compli-
cated CD, thereby aiding in deciding the extent of treatment and follow-up intervals.
The main sources of serum free fatty acids, including palmitoleate, include the adipose tissue, the liver, and 
dietary  intake19,22. Accumulating evidence suggests adipose tissue in the mesentery might play a highly active role 
in the pathogenesis of  CD23. For example, mesenteric adipocytes in patients with CD have been shown to secrete 
both proinflammatory mediators (e.g., TNF-α) and anti-inflammatory cytokines (e.g., interleukin-10)23–25. In 
CD, a high visceral to subcutaneous fat area has been reported as a biomarker for complications of CD including 
fistula and luminal stricture, which are often the indicators of surgery requirement. Our pilot study conducted 
using abdominal MAT samples from a small number of patients indicated a tendency of PO levels to increase 
in the active disease site of CD compared with that in patients with UC and controls. These findings suggest 
that PO may be released from the MAT. The possible explanation for the differential PO levels between patients 
with UC and CD is that inflammation caused by CD often affects the entire wall of the digestive system, which 
causes fat wrapping of the mesenchymal tissue as a defense mechanism in the active disease  site23,26. A study in 
a larger population, including the other potential sources of PO, such as the liver and subcutaneous fat, could 
substantiate our hypothesis.
Limitations of this study include the relatively small number of individuals studied and the lack of functional 
studies of PO.
In general, PO supplementation is beneficial in suppressing inflammation, such as atherosclerosis in mice, 
where it prevents the activation of endoplasmic stress and  inflammasomes27. PO blocks the inflammatory cas-
cade triggered by endotoxins by downregulating the expression of Toll like receptor-4 (TLR-4) and nuclear 
Figure 4.  Palmitoleic acid (PO) levels increase in the mesenteric adipose tissue (MAT) of patients with Crohn’s 
disease (CD). (A) Comparison of PO levels in the MAT among patients with colon cancer, ulcerative colitis 
(UC), and CD. PO levels in the MAT in the disease-affected area. The p-values in the graph show significant 
differences determined using the Steel–Dwass test. (B) Comparison of PO levels in the MAT between unaffected 
and disease-affected areas in patients with CD. p = 0.0313, paired Wilcoxon test.
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factor-kappa B (NF-κB) and decreasing the production of pro-inflammatory cytokines in cultured primary 
 macrophages28. PO treatment has been reported to be beneficial for patients with UC; however, there are no data 
on its use in patients with  CD29. A previous study showed that the occurrence of SNPs near fatty acid desaturase 
1 and glucokinase regulator was related to both increased serum PO levels and enhanced risk of CD in humans, 
thus indicating that high PO levels may be associated with an increased risk of CD. Our result is consistent with 
that of a previous study; it indicates that serum PO levels may also affect disease  outcomes17.
In conclusion, our data indicate altered PO metabolism in CD and its role in identifying disease activity. PO 
has the potential to serve as a disease activity marker for local inflammation, as well as a prognostic factor, in CD.
Materials and methods
Study group. The protocol of this retrospective study was approved by the medical ethics committee of 
Nagasaki University Hospital Clinical Research Ethics Committee (approval no. 13040149). Patients who did 
not provide informed consent were excluded from the study. For subjects under 18 years of age, informed con-
sent was obtained from their parents and/or legal guardian. This study was performed in accordance with the 
ethical guidelines of the Declaration of Helsinki. The serum study group consisted of 57 patients with IBD 
(35 patients with CD and 22 with UC) from April 2010 to March 2011. Twenty-two healthy volunteers were 
recruited as controls. The diagnosis of UC or CD was confirmed according to standardized criteria by prior clini-
cal assessment, endoscopy, and histology. Omental fat specimens were obtained from 6 patients with CD and 
4 with UC and were compared with those from 7 patients with colon cancer who underwent surgical resection 
between April 2013 and November 2014. The clinical records of the patients were then investigated from the 
time of sample collection until September 2020. Baseline data collected included those for sex, age, disease dura-
tion, surgical history, concomitant medications, CRP level, CAI, and CDAI. The dates of all surgical intervention 
procedures, including colectomy, enterectomy, and abscess drainage during the follow-up, were recorded for 
patients with IBD.
Measurement of PO levels in the serum and MAT. Serum samples were collected from all patients 
with IBD and healthy volunteers in ethylenediaminetetraacetic acid tubes and preserved at − 80 °C until use. The 
MAT was collected during the colectomy. All surgeries were performed because of clinically necessary reasons. 
The MAT samples were stored at − 80 °C until use. Samples were homogenized in a Fast Prep System with Lysing 
Matrix D (MP Biomedicals, Solon, OH, USA). The homogenates were extracted using a mixture of methanol, 
chloroform, and purified water. The extracts were concentrated to complete dryness by blowing nitrogen. After 
transmethylation with HCl-methanol (3 h at 70 °C), the fatty acid composition was analyzed by gas chroma-
tography (Agilent 7890B Gas Chromatograph, Agilent Technologies, Santa Clara, CA, USA) using a GC flame 
ionization detector system (Shimadzu, Tokyo, Japan) equipped with a capillary column (Omegawax 320; length, 
30 m; internal diameter, 0.22 mm; film, 0.25 μM, Sigma-Aldrich, St. Louis, MO, USA) by TORAY Research 
Center (Shiga, Japan). Methyl stearate was used as the internal standard for free fatty acid analysis. The injector 
temperature was 250 °C, and the detector temperature was 270 °C. Initially, the column temperature was set to 
50 °C for 1 min, and then ramped up to 270 °C at a rate of 8 °C/min. Helium was used as carrier gas at a flow 
rate of 30 cm/s. The concentration of fatty acids was assessed through a comparison with the standard Supelco 
37 FAME component (37-component FAME mix, Sigma-Aldrich Japan, Tokyo, Japan).
Statistical analyses. Statistical analyses were performed by a statistician (HK). Differences in quantitative 
values between two groups were assessed using the Wilcoxon rank-sum test. Differences in values among three 
or more groups were assessed using the Steel–Dwass test. A Cox proportional hazards model with person-days 
as the underlying metric was employed to estimate hazard ratios for surgical interventions for CD using the 
PHREG procedures in the SAS software package (version 9.4; SAS Institute, Inc., Cary, NC, USA). The AUC 
and cut-off value of PO levels for surgical interventions were calculated using the LOGISTIC procedure with the 
SAS software package. All statistical tests were two-sided, and results with p < 0.05 were considered statistically 
significant.
Ethics declarations. This study was performed in accordance with the ethical guidelines of the Declaration 
of Helsinki.
Consent to participate/consent to publish. Written informed consent was obtained from each patient.
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